Nuo Therapeutics Inc. (NUOT) 0.1999 $NUOT
Global Stem Cell Therapy Market Future Outlook
M2 - Tue Jul 07, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vdbl4h/global_stem_cell) has announced the addition of the "Global Stem Cell Therapy Market Future Outlook" report to their offering. As per recent research report "Global Stem Cell Therapy Market Future Outlook", advancement in stem cell research seems to be increasing continuously across the globe which is apparent from the number of increasing clinical trials. Stem cell therapies for numerous indications are at different stages of clinical trials and they would be introduced in market in coming years. Increased findings and quest for better therapeutics could be considered as main reason behind growth of this segment. Improved technology and development of innovative modalities are further expected to propel the development of stem cell therapies. Only few stem cell therapies have received approval and most of them are small part of forth coming medical revolution. Stem cell therapy developers would be able to generate significant revenues in coming years. In this way, future prospects of stem cell therapies look optimistic and it is expected that more stem cell therapies would be commercialized in coming years. "Global Stem Cell Therapy Market Future Outlook" Report Highlight: - Global Stem Cell Market Analysis - Trends in Stem Cell Research - Global Stem Cell Market Dynamics: Favorable Factors & Commercialization Challenges - Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase - Global Stem Cell Therapies in Clinical Pipeline: 114 Therapies - Majority Stem Cell Therapies in Preclinical Phase: 38 Therapies - Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication - Marketed Stem Cell Therapies Clinical: 2 Therapies (Adipocell? & VesCell) Key Topics Covered: 1. Introduction to Stem Cells 2. Classification of Stem Cells 3. Different Type of Stem Cell Transplants 4. Mechanism of Stem Cell Therapy 5. Trends in Stem Cell Research 6. Global Stem Cell Market Analysis 7. Global Stem Cell Market Dynamics 8. Stem Cell Market Future Prospects 9. Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase 10. Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication 11. Discontinued & Suspended Stem Cell Therapies in Clinical Pipeline 12. Competitive Landscape - Aldagen - AlloCure - Anterogen - Arteriocyte Medical Systems - Athersys - Baxter Healthcare Corporation - Bioheart - Caladrius - Cambridge Enterprise - Celgene Corporation - CellPraxis - Cellerant Therapeutics - Cryopraxis - Cytori Therapeutics - Gamida Cell - Genexine - Geron - Intrexon Corporation - K-STEMCELL - Lifecells - Novartis - Nuo Therapeutics - Ocata Therapeutics - OmniCyte - OncoMed - Osiris Therapeutics - Pharmicell - Pluristem Therapeutics - Promethera Biosciences - ReNeuron - Stem Cell Sciences - Stemedica Cell Technologies - TCA Cellular Therapy - TiGenix - Vericel Corporation For more information visit http://www.researchandmarkets.com/research/vd..._stem_cell
OCAT: 5.22 (+0.14), VCEL: 3.60 (+0.06), PSTI: 2.40 (+0.03), CYTX: 0.47 (+0.01), OSIR: 19.31 (+0.65), MDSY: 1.62 (-0.18), XON: 46.54 (+1.02), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
Nuo Therapeutics to Support 35th Annual National Veterans Wheelchair Games
GlobeNewswire - Wed Jun 17, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced its participation in the 35 Annual National Veterans Wheelchair Games (NVWG), presented by the Department of Veterans Affairs (VA) and Paralyzed Veterans of America (PVA), taking place June 21 - 26 in Dallas, TX.
Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kl4nwn/peripheral_artery) has announced the addition of the "Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Annexin Pharmaceuticals AB - Apceth GmbH & Co. KG - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Cytokinetics, Inc. - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Genovate Biotechnology Co., LTD. - Grifols, S.A. - Human Stem Cells Institute - Kowa Company, Ltd. - Lacer, S.A. - Ligand Pharmaceuticals, Inc. - LTT Bio-Pharma Co., Ltd. - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Rigel Pharmaceuticals, Inc. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Taisho Toyama Pharmaceutical Co., Ltd. - Theravasc, Inc. - vasopharm GmbH - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kl...ral_artery
CYTK: 6.10 (+0.02), PSTI: 2.40 (+0.03), RIGL: 3.11 (+0.10), PRTO: 17.33 (+1.23), AZN: 66.45 (+1.90), ATHX: 1.14 (-0.01), CELGZ: 2.15 (+0.14)
Lysosomal Storage Disorder Pipeline Review, H1 2015 - 15 Companies & 27 Drug Profiles
M2 - Thu Jun 11, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxz52s/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - BBB Therapeutics B.V. - Chiesi Farmaceutici SpA - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Neuralstem, Inc. - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - REGiMMUNE Corporation - Sagetis Biotech, S.L. - Sangamo BioSciences, Inc. - Synageva BioPharma Corp. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - NSI-566 - Orph-001 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Activate LRP1 for Lysosomal Storage Disorder - RGI-5000 - SAG-002 - SBLSD-3 - SBLSD-4 - sebelipase alfa - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis And Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-002 - UX-004 - ZA-011 For more information visit http://www.researchandmarkets.com/research/vx...al_storage
FATE: 7.25 (unch), GEVA: 238.60 (+2.80), SGMO: 9.86 (-0.02), FOLD: 14.48 (+0.44), CUR: 1.69 (-0.01)
The Extensive Number of Cosmetic Surgeries Performed Considered one of the Most Prominent Factors Propelling Growth of the Global PRP Market During 2014 to 2020
M2 - Thu Jun 11, 9:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2chrr5/platelet_rich) has announced the addition of the "Platelet Rich Plasma Market- Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2020" report to their offering. According to the statistics provided by the International Society of Plastic and Aesthetic Surgeons (ISAPS), 11 million non-invasive cosmetic procedures were performed worldwide in 2013, including approximately 3.0 million dermal filler procedures. This extensive number of cosmetic surgeries performed is considered as one of the most prominent factor propelling the growth of the global PRP market during the forecast period from 2014 to 2020. Furthermore, increasing application areas such as erectile dysfunction and vampire facelift also support the market growth in the near future. Orthopedic surgery was the largest application segment in 2013. Increasing prevalence of orthopedic diseases and promotion of PRP technique by various sports personalities are some of the factors responsible for the dominance of this application segment in the global PRP market. PRP products are widely used in cosmetic surgeries to improve facial aesthetics, enhance the rate of injury healing and modify facial structure (vampire facelift treatment). In addition, cosmetic surgeries performed with the use of PRP products modify the facial aesthetics in a short period of time due to reduction in the healing time. Thus, owing to all the above mentioned factors cosmetic surgery application segment is likely to witness the highest growth rate during the forecast period from 2014 to 2020. Companies Mentioned: -AdiStem Ltd. -Arteriocyte Medical Systems, Inc. -Arthrex, Inc. -Biomet, Inc. -Cesca Therapeutics, Inc. -DePuy Synthes, Inc. (DePuy Mitek Sports Medicine) -Dr. PRP America LLC -EmCyte Corporation -Exactech, Inc. -Harvest Technologies Corp. -Nuo Therapeutics, Inc. (Cytomedix, Inc.) -Regen Lab SA -Stryker Corporation For more information visit http://www.researchandmarkets.com/research/2c...telet_rich About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
KOOL: 0.71 (-0.03), MDSY: 1.62 (-0.18), EXAC: 20.72 (+0.54), SYK: 96.37 (+0.71)
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Review, H1 2015 - 4 Companies & 7 Drug Profiles
M2 - Tue Jun 09, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p65dfx/chronic_coronary) has announced the addition of the "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Human Stem Cells Institute - Juventas Therapeutics, Inc. - Lacer, S.A. - Nuo Therapeutics, Inc. Drug Profiles - ALD-201 - Biglycan Therapy for Cardiovascular Diseases - Cryocel - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - JVS-100 - LA-419 - Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy For more information visit http://www.researchandmarkets.com/research/p6...c_coronary
Nuo Therapeutics Receives Prestigious Creative Award for Aurix Patient Brochure
GlobeNewswire - Tue May 19, 3:32PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that it, along with its marketing partner BLDG Health, won Gold in the Hermes Creative Awards 2015 competition presented by the Association of Marketing and Communication Professionals (AMCP) for its Aurix(TM) Patient Brochure. These materials were designed to help patients understand how Aurix, a biodynamic hematogel, harnesses their innate healing power to jumpstart the natural healing process in wounds of all sizes and severities, and the critical role patients play as the 'secret ingredient to healing.'
Global Cell Therapy Market Outlook 2020
M2 - Tue May 19, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82ktgh/global_cell) has announced the addition of the "Global Cell Therapy Market Outlook 2020 " report to their offering. Utilization of cell therapy in tissue and regenerative medicine is expected to have huge marketing potential. Presently, there are no other options which could help in the growth of deregulated organs. Several therapeutic molecules are present in this segment but they are unable to form new tissue or sometimes organ transplant is required. Cell therapies are becoming competent with time and their utilization in large number of indications have made them an indispensible part of pharmaceutical industry. Significant investments in research and development segment along with years of data are helping in introduction of innovative products. However, they are quite new for pharmaceutical industry and their long-term effect is not known. It may offer hindrance but their superior pharmacological efficacy is going to promote their usage across the globe. It is at nascent stages but holds promise for future generations which are expected to observe boost in cell therapy products. Glitches in manufacturing and large scale production are needed to be solved in coming years. Many significant results have been achieved due to which confidence of investors, investigators, physicians and patients have increased in cell therapies. All these development shows that cell therapeutics are expected to generate significant revenues across the globe. Global Cell Therapy Market Outlook 2020 Report Highlights: - Introduction & Classification of Cell Therapy - Role of Stem Cells in Cell Therapy - Global Cell Therapy Market Analysis - Global Cell Therapy Clinical Pipeline by Country, Indication & Phase - Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication - Global Cell Therapy Clinical Pipeline: 262 Cell Therapies - Marketed Cell Therapies: 13 Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication - Adipose Stem Cell Therapy (Adipocell?) - Allogeneic Cultured Keratinocytes & Fibroblasts (Gintuit?) - Angiogenic Cell Precursor Therapy (VesCell) - Autologous Chondrocyte Implantation (ChondroCelect?) - Autologous Chondrocytes (BioCart) - Autologous Cultured Chondrocyte Implant (Carticel?) - Autologous Cultured Chondrocytes (Chondrotransplant? DISC) - Matrix Characterised Autologous Cultured Chondrocytes (MACI) - Azficel-T (Laviv?) - Human Skin Replacement for Burns (CellSpray?) - Leukocyte Cell Therapy (CureXcell) - Sipuleucel-T (Provenge?) - T-Lymphocyte Cell Therapy (Immuncell-LC?) Companies Mentioned - AlloCure - Arteriocyte Medical Systems - Athersys Inc. - Baxter Healthcare Corporation - Bone Therapeutics - Celgene Corporation - Cell Medica - Cellerant Therapeutics - FibrocellScinence - Forticell Bioscience - Genzyme Corporation - Green Cross Cell - Histogenics Corporation - ISTO Technologies - InnovacellBiotechnologie AG - Intercytex - Intrexon Corporation - Macrocure - Mesoblast - Molmed - Nuo Therapeutics Inc - OmniCyte - Opexa Therapeutics - Organogenesis - Pharmicell - Stem Cell Inc. - TCA Cellular Therapy - Teva Pharmaceuticals - Tigenix - Vericel Corporation For more information visit http://www.researchandmarkets.com/research/82...lobal_cell
HSGX: 6.23 (-0.10), OPXA: 0.44 (-0.01), VCEL: 3.60 (+0.06), MDSY: 1.62 (-0.18), XON: 46.54 (+1.02), ATHX: 1.14 (-0.01), CELGZ: 2.15 (+0.14)
Nuo Therapeutics' (NUOT) CEO Martin Rosendale on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 10:17AM CDT
Nuo Therapeutics Reports First Quarter 2015 Results and Provides Commercial Update
GlobeNewswire - Wed May 13, 4:50PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the first quarter ended March 31, 2015 and provided an update on commercialization activities.
NUO Therapeutics to Hold First Quarter 2015 Conference Call on Thursday, May 14 at 8:00 a.m. Eastern Time
GlobeNewswire - Mon May 11, 7:30AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the first quarter of 2015 on Wednesday, May 13, 2015, after the close of market.
Nuo Therapeutics Presents New Clinical Evidence Supporting Aurix at 2015 SAWC Spring Meeting
GlobeNewswire - Mon May 04, 8:03AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced three patient case studies demonstrating the efficacious healing capabilities of Aurix(TM), a biodynamic hematogel, in treating chronic wounds were presented at the 28 Annual Symposium on Advanced Wound Care (SAWC) Spring Meeting, held in San Antonio, Texas from April 29 - May 3, 2015.
Nuo Therapeutics Announces Senior Management and Board Changes
GlobeNewswire - Thu Apr 30, 3:30PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today announced that David Jorden, current Executive Chairman of the Company's Board of Directors, has been appointed Acting Chief Financial Officer officially effective May 24, 2015 but will assume some roles immediately. Mr. Jorden, who was named Executive Chairman in 2012 and has served on the Company's Board since 2008, replaces Steven Shallcross, who has resigned effective May 25, 2015 to pursue another career opportunity. The Company plans to initiate an executive search for a permanent successor to Mr. Shallcross.
Nuo Hit By Perfect Storm In 2014, But We See Blue Sky Ahead
Jason Napodano, CFA - at Seeking Alpha - Thu Apr 02, 2:34PM CDT
Nuo Therapeutics Reports Full-Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 4:00PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the year ended December 31, 2014.
Next Week In Biotech: AcelRx's New CEO, RXi And Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
IMDZ: 24.04 (+3.00), ARGS: 6.45 (+0.69), RXII: 0.53 (+0.05), CTSO: 6.20 (+0.40), ADK: 3.89 (+0.19), CLDN: 1.26 (+0.01)
NUO Therapeutics to Hold Fourth Quarter and Full Year 2014 Conference Call on Wednesday, April 1 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Mar 25, 7:45AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the fourth quarter and full year 2014 on Tuesday, March 31, 2015, after the close of market.
Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 11.17 (+0.69), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), STML: 11.86 (+0.03)
Nuo Therapeutics Initiates Phase 4 Study of Aurix(TM) Under CMS Coverage With Evidence Development Program
GlobeNewswire - Thu Feb 19, 7:30AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix(TM), a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores).
Global Stem Cell Therapy Market Future Outlook
M2 - Tue Jul 07, 8:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vdbl4h/global_stem_cell) has announced the addition of the "Global Stem Cell Therapy Market Future Outlook" report to their offering. As per recent research report "Global Stem Cell Therapy Market Future Outlook", advancement in stem cell research seems to be increasing continuously across the globe which is apparent from the number of increasing clinical trials. Stem cell therapies for numerous indications are at different stages of clinical trials and they would be introduced in market in coming years. Increased findings and quest for better therapeutics could be considered as main reason behind growth of this segment. Improved technology and development of innovative modalities are further expected to propel the development of stem cell therapies. Only few stem cell therapies have received approval and most of them are small part of forth coming medical revolution. Stem cell therapy developers would be able to generate significant revenues in coming years. In this way, future prospects of stem cell therapies look optimistic and it is expected that more stem cell therapies would be commercialized in coming years. "Global Stem Cell Therapy Market Future Outlook" Report Highlight: - Global Stem Cell Market Analysis - Trends in Stem Cell Research - Global Stem Cell Market Dynamics: Favorable Factors & Commercialization Challenges - Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase - Global Stem Cell Therapies in Clinical Pipeline: 114 Therapies - Majority Stem Cell Therapies in Preclinical Phase: 38 Therapies - Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication - Marketed Stem Cell Therapies Clinical: 2 Therapies (Adipocell? & VesCell) Key Topics Covered: 1. Introduction to Stem Cells 2. Classification of Stem Cells 3. Different Type of Stem Cell Transplants 4. Mechanism of Stem Cell Therapy 5. Trends in Stem Cell Research 6. Global Stem Cell Market Analysis 7. Global Stem Cell Market Dynamics 8. Stem Cell Market Future Prospects 9. Global Stem Cell Therapies Clinical Pipeline by Company, Indication & Phase 10. Marketed Stem Cell Therapies Clinical Insight by Brand Name, Company & Indication 11. Discontinued & Suspended Stem Cell Therapies in Clinical Pipeline 12. Competitive Landscape - Aldagen - AlloCure - Anterogen - Arteriocyte Medical Systems - Athersys - Baxter Healthcare Corporation - Bioheart - Caladrius - Cambridge Enterprise - Celgene Corporation - CellPraxis - Cellerant Therapeutics - Cryopraxis - Cytori Therapeutics - Gamida Cell - Genexine - Geron - Intrexon Corporation - K-STEMCELL - Lifecells - Novartis - Nuo Therapeutics - Ocata Therapeutics - OmniCyte - OncoMed - Osiris Therapeutics - Pharmicell - Pluristem Therapeutics - Promethera Biosciences - ReNeuron - Stem Cell Sciences - Stemedica Cell Technologies - TCA Cellular Therapy - TiGenix - Vericel Corporation For more information visit http://www.researchandmarkets.com/research/vd..._stem_cell
OCAT: 5.22 (+0.14), VCEL: 3.60 (+0.06), PSTI: 2.40 (+0.03), CYTX: 0.47 (+0.01), OSIR: 19.31 (+0.65), MDSY: 1.62 (-0.18), XON: 46.54 (+1.02), NVS: 103.22 (+3.20), CELGZ: 2.15 (+0.14)
Nuo Therapeutics to Support 35th Annual National Veterans Wheelchair Games
GlobeNewswire - Wed Jun 17, 7:30AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced its participation in the 35 Annual National Veterans Wheelchair Games (NVWG), presented by the Department of Veterans Affairs (VA) and Paralyzed Veterans of America (PVA), taking place June 21 - 26 in Dallas, TX.
Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015
M2 - Fri Jun 12, 4:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kl4nwn/peripheral_artery) has announced the addition of the "Peripheral Artery Occlusive Disease (PAOD) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Artery Occlusive Disease (PAOD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Artery Occlusive Disease (PAOD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Annexin Pharmaceuticals AB - Apceth GmbH & Co. KG - AstraZeneca PLC - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Cytokinetics, Inc. - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Genovate Biotechnology Co., LTD. - Grifols, S.A. - Human Stem Cells Institute - Kowa Company, Ltd. - Lacer, S.A. - Ligand Pharmaceuticals, Inc. - LTT Bio-Pharma Co., Ltd. - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Pluristem Therapeutics Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - RegenoCELL Therapeutics, Inc. - Rigel Pharmaceuticals, Inc. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Taisho Toyama Pharmaceutical Co., Ltd. - Theravasc, Inc. - vasopharm GmbH - ViroMed Co., Ltd. For more information visit http://www.researchandmarkets.com/research/kl...ral_artery
CYTK: 6.10 (+0.02), PSTI: 2.40 (+0.03), RIGL: 3.11 (+0.10), PRTO: 17.33 (+1.23), AZN: 66.45 (+1.90), ATHX: 1.14 (-0.01), CELGZ: 2.15 (+0.14)
Lysosomal Storage Disorder Pipeline Review, H1 2015 - 15 Companies & 27 Drug Profiles
M2 - Thu Jun 11, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vxz52s/lysosomal_storage) has announced the addition of the "Lysosomal Storage Disorder - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lysosomal Storage Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amicus Therapeutics, Inc. - AngioChem Inc. - BBB Therapeutics B.V. - Chiesi Farmaceutici SpA - Fate Therapeutics, Inc. - Minoryx Therapeutics s.l. - Neuralstem, Inc. - Nuo Therapeutics, Inc. - Orphazyme ApS - Oxyrane Belgium NV - REGiMMUNE Corporation - Sagetis Biotech, S.L. - Sangamo BioSciences, Inc. - Synageva BioPharma Corp. - Ultragenyx Pharmaceutical Inc. Drug Profiles - 2B3-201 - ALD-601 - Chaperone-ERT Combinations - Delta-tocopherol - FT-1050 - ML-SA1 - NSI-566 - Orph-001 - Recombinant Enzyme for Farber Disease and Cystic Fibrosis - Recombinant Enzyme for LSD-2 Disease - Recombinant Enzyme for LSD-3 Disease - Recombinant Enzyme for LSD-4 Disease - Recombinant Enzyme for LSD-5 Disease - Recombinant Enzyme for Lysosomal Storage Disorder - Recombinant Enzyme to Activate LRP1 for Lysosomal Storage Disorder - RGI-5000 - SAG-002 - SBLSD-3 - SBLSD-4 - sebelipase alfa - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecules for GM1-gangliosidosis And Morquio B - Small Molecules for Lysosomal Storage Disorders - Stem Cell Therapy for Lysosomal Storage Disorder - UX-002 - UX-004 - ZA-011 For more information visit http://www.researchandmarkets.com/research/vx...al_storage
FATE: 7.25 (unch), GEVA: 238.60 (+2.80), SGMO: 9.86 (-0.02), FOLD: 14.48 (+0.44), CUR: 1.69 (-0.01)
The Extensive Number of Cosmetic Surgeries Performed Considered one of the Most Prominent Factors Propelling Growth of the Global PRP Market During 2014 to 2020
M2 - Thu Jun 11, 9:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2chrr5/platelet_rich) has announced the addition of the "Platelet Rich Plasma Market- Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2020" report to their offering. According to the statistics provided by the International Society of Plastic and Aesthetic Surgeons (ISAPS), 11 million non-invasive cosmetic procedures were performed worldwide in 2013, including approximately 3.0 million dermal filler procedures. This extensive number of cosmetic surgeries performed is considered as one of the most prominent factor propelling the growth of the global PRP market during the forecast period from 2014 to 2020. Furthermore, increasing application areas such as erectile dysfunction and vampire facelift also support the market growth in the near future. Orthopedic surgery was the largest application segment in 2013. Increasing prevalence of orthopedic diseases and promotion of PRP technique by various sports personalities are some of the factors responsible for the dominance of this application segment in the global PRP market. PRP products are widely used in cosmetic surgeries to improve facial aesthetics, enhance the rate of injury healing and modify facial structure (vampire facelift treatment). In addition, cosmetic surgeries performed with the use of PRP products modify the facial aesthetics in a short period of time due to reduction in the healing time. Thus, owing to all the above mentioned factors cosmetic surgery application segment is likely to witness the highest growth rate during the forecast period from 2014 to 2020. Companies Mentioned: -AdiStem Ltd. -Arteriocyte Medical Systems, Inc. -Arthrex, Inc. -Biomet, Inc. -Cesca Therapeutics, Inc. -DePuy Synthes, Inc. (DePuy Mitek Sports Medicine) -Dr. PRP America LLC -EmCyte Corporation -Exactech, Inc. -Harvest Technologies Corp. -Nuo Therapeutics, Inc. (Cytomedix, Inc.) -Regen Lab SA -Stryker Corporation For more information visit http://www.researchandmarkets.com/research/2c...telet_rich About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
KOOL: 0.71 (-0.03), MDSY: 1.62 (-0.18), EXAC: 20.72 (+0.54), SYK: 96.37 (+0.71)
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Pipeline Review, H1 2015 - 4 Companies & 7 Drug Profiles
M2 - Tue Jun 09, 6:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/p65dfx/chronic_coronary) has announced the addition of the "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Human Stem Cells Institute - Juventas Therapeutics, Inc. - Lacer, S.A. - Nuo Therapeutics, Inc. Drug Profiles - ALD-201 - Biglycan Therapy for Cardiovascular Diseases - Cryocel - Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases - JVS-100 - LA-419 - Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy For more information visit http://www.researchandmarkets.com/research/p6...c_coronary
Nuo Therapeutics Receives Prestigious Creative Award for Aurix Patient Brochure
GlobeNewswire - Tue May 19, 3:32PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that it, along with its marketing partner BLDG Health, won Gold in the Hermes Creative Awards 2015 competition presented by the Association of Marketing and Communication Professionals (AMCP) for its Aurix(TM) Patient Brochure. These materials were designed to help patients understand how Aurix, a biodynamic hematogel, harnesses their innate healing power to jumpstart the natural healing process in wounds of all sizes and severities, and the critical role patients play as the 'secret ingredient to healing.'
Global Cell Therapy Market Outlook 2020
M2 - Tue May 19, 10:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82ktgh/global_cell) has announced the addition of the "Global Cell Therapy Market Outlook 2020 " report to their offering. Utilization of cell therapy in tissue and regenerative medicine is expected to have huge marketing potential. Presently, there are no other options which could help in the growth of deregulated organs. Several therapeutic molecules are present in this segment but they are unable to form new tissue or sometimes organ transplant is required. Cell therapies are becoming competent with time and their utilization in large number of indications have made them an indispensible part of pharmaceutical industry. Significant investments in research and development segment along with years of data are helping in introduction of innovative products. However, they are quite new for pharmaceutical industry and their long-term effect is not known. It may offer hindrance but their superior pharmacological efficacy is going to promote their usage across the globe. It is at nascent stages but holds promise for future generations which are expected to observe boost in cell therapy products. Glitches in manufacturing and large scale production are needed to be solved in coming years. Many significant results have been achieved due to which confidence of investors, investigators, physicians and patients have increased in cell therapies. All these development shows that cell therapeutics are expected to generate significant revenues across the globe. Global Cell Therapy Market Outlook 2020 Report Highlights: - Introduction & Classification of Cell Therapy - Role of Stem Cells in Cell Therapy - Global Cell Therapy Market Analysis - Global Cell Therapy Clinical Pipeline by Country, Indication & Phase - Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication - Global Cell Therapy Clinical Pipeline: 262 Cell Therapies - Marketed Cell Therapies: 13 Marketed Cell Therapy Clinical Insight by Brand Name, Company & Indication - Adipose Stem Cell Therapy (Adipocell?) - Allogeneic Cultured Keratinocytes & Fibroblasts (Gintuit?) - Angiogenic Cell Precursor Therapy (VesCell) - Autologous Chondrocyte Implantation (ChondroCelect?) - Autologous Chondrocytes (BioCart) - Autologous Cultured Chondrocyte Implant (Carticel?) - Autologous Cultured Chondrocytes (Chondrotransplant? DISC) - Matrix Characterised Autologous Cultured Chondrocytes (MACI) - Azficel-T (Laviv?) - Human Skin Replacement for Burns (CellSpray?) - Leukocyte Cell Therapy (CureXcell) - Sipuleucel-T (Provenge?) - T-Lymphocyte Cell Therapy (Immuncell-LC?) Companies Mentioned - AlloCure - Arteriocyte Medical Systems - Athersys Inc. - Baxter Healthcare Corporation - Bone Therapeutics - Celgene Corporation - Cell Medica - Cellerant Therapeutics - FibrocellScinence - Forticell Bioscience - Genzyme Corporation - Green Cross Cell - Histogenics Corporation - ISTO Technologies - InnovacellBiotechnologie AG - Intercytex - Intrexon Corporation - Macrocure - Mesoblast - Molmed - Nuo Therapeutics Inc - OmniCyte - Opexa Therapeutics - Organogenesis - Pharmicell - Stem Cell Inc. - TCA Cellular Therapy - Teva Pharmaceuticals - Tigenix - Vericel Corporation For more information visit http://www.researchandmarkets.com/research/82...lobal_cell
HSGX: 6.23 (-0.10), OPXA: 0.44 (-0.01), VCEL: 3.60 (+0.06), MDSY: 1.62 (-0.18), XON: 46.54 (+1.02), ATHX: 1.14 (-0.01), CELGZ: 2.15 (+0.14)
Nuo Therapeutics' (NUOT) CEO Martin Rosendale on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 10:17AM CDT
Nuo Therapeutics Reports First Quarter 2015 Results and Provides Commercial Update
GlobeNewswire - Wed May 13, 4:50PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the first quarter ended March 31, 2015 and provided an update on commercialization activities.
NUO Therapeutics to Hold First Quarter 2015 Conference Call on Thursday, May 14 at 8:00 a.m. Eastern Time
GlobeNewswire - Mon May 11, 7:30AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the first quarter of 2015 on Wednesday, May 13, 2015, after the close of market.
Nuo Therapeutics Presents New Clinical Evidence Supporting Aurix at 2015 SAWC Spring Meeting
GlobeNewswire - Mon May 04, 8:03AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced three patient case studies demonstrating the efficacious healing capabilities of Aurix(TM), a biodynamic hematogel, in treating chronic wounds were presented at the 28 Annual Symposium on Advanced Wound Care (SAWC) Spring Meeting, held in San Antonio, Texas from April 29 - May 3, 2015.
Nuo Therapeutics Announces Senior Management and Board Changes
GlobeNewswire - Thu Apr 30, 3:30PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today announced that David Jorden, current Executive Chairman of the Company's Board of Directors, has been appointed Acting Chief Financial Officer officially effective May 24, 2015 but will assume some roles immediately. Mr. Jorden, who was named Executive Chairman in 2012 and has served on the Company's Board since 2008, replaces Steven Shallcross, who has resigned effective May 25, 2015 to pursue another career opportunity. The Company plans to initiate an executive search for a permanent successor to Mr. Shallcross.
Nuo Hit By Perfect Storm In 2014, But We See Blue Sky Ahead
Jason Napodano, CFA - at Seeking Alpha - Thu Apr 02, 2:34PM CDT
Nuo Therapeutics Reports Full-Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 4:00PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the year ended December 31, 2014.
Next Week In Biotech: AcelRx's New CEO, RXi And Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
IMDZ: 24.04 (+3.00), ARGS: 6.45 (+0.69), RXII: 0.53 (+0.05), CTSO: 6.20 (+0.40), ADK: 3.89 (+0.19), CLDN: 1.26 (+0.01)
NUO Therapeutics to Hold Fourth Quarter and Full Year 2014 Conference Call on Wednesday, April 1 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Mar 25, 7:45AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the fourth quarter and full year 2014 on Tuesday, March 31, 2015, after the close of market.
Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 11.17 (+0.69), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), STML: 11.86 (+0.03)
Nuo Therapeutics Initiates Phase 4 Study of Aurix(TM) Under CMS Coverage With Evidence Development Program
GlobeNewswire - Thu Feb 19, 7:30AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix(TM), a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores).
